Pfizer gains unconditional EU antitrust nod for proposed USD 43 billion Seagen acquisition
"The proposed merger would not raise competition concerns," the EU antitrust watchdog said in a statement.
Brussels: U.S. pharmaceutical company Pfizer has gained unconditional EU antitrust approval for its proposed $43 billion acquisition of cancer drug maker Seagen.
Pfizer announced the deal in March, its largest purchase in a string of recent acquisitions thanks to a once-in-a-lifetime cash windfall from its COVID-19 vaccine and treatment.
The European Commission said the deal would not significantly reduce competition in the 27-country European Union nor would it have a negative impact on prices.
Read also: Pfizer USD 43 billion bid for Seagen to be decided by EU antitrust regulators
"The proposed merger would not raise competition concerns," the EU antitrust watchdog said in a statement.
Washington-based Seagen is a pioneer of antibody-drug conjugates, which work like "guided missiles" designed to destroy cancer while sparing healthy cells.
Read also: EU medicines regulator recommends conditional marketing nod for Pfizer blood cancer therapy
